Asahi Kasei agreed to acquire Aicuris Anti‑infective Cures AG for €780 million (about $920 million) to expand its infectious‑disease portfolio. The acquisition brings marketed letermovir (Prevymis) for CMV prophylaxis and pritelivir — a helicase‑primase inhibitor for HSV with breakthrough therapy designation and an imminent NDA filing — plus antisense candidate AIC‑468 targeting BK virus. Aicuris’ marketed revenues and late‑stage antiviral candidates give Asahi a faster route to specialty anti‑infective growth. The company said the deal will close in the first half of 2026, subject to regulatory clearances. For buyers, the acquisition highlights a strategic preference for tuck‑ins that combine established commercial assets with near‑term regulatory value to de‑risk R&D investment in infectious disease.